Research programme: soluble guanylate cyclase stimulants - Bayer

Drug Profile

Research programme: soluble guanylate cyclase stimulants - Bayer

Alternative Names: BAY 41-2272; BAY 54-6544

Latest Information Update: 29 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Antihypertensives; Antiplatelets; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 29 Mar 2010 Discontinued - Preclinical for Congestive heart failure in Germany (PO)
  • 29 Mar 2010 Discontinued - Preclinical for Hypertension in Germany (PO)
  • 05 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Hypertension pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top